Overview

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

Status:
Completed
Trial end date:
2017-12-28
Target enrollment:
Participant gender:
Summary
Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb